Durect Corporation
Pharmaceuticals, Bubb Rd, Cupertino, , 95014, California, 10260, United States, 51-200 Employees
Phone Number: 40********
Who is DURECT CORPORATION
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life...
Read More
-
Headquarters: 10260 Bubb Rd, Cupertino, California, 95014, United States
-
Date Founded: 1998
-
Employees: 51-200
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 621111 |
Show More
Does something look wrong? Fix it. | View contact records from DURECT CORPORATION
DURECT Corporation Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding DURECT Corporation
Answer: DURECT Corporation's headquarters are located at Bubb Rd, Cupertino, , 95014, California, 10260, United States
Answer: DURECT Corporation's phone number is 40********
Answer: DURECT Corporation's official website is https://durect.com
Answer: DURECT Corporation's revenue is $10 Million to $25 Million
Answer: DURECT Corporation's SIC: 2834
Answer: DURECT Corporation's NAICS: 621111
Answer: DURECT Corporation has 51-200 employees
Answer: DURECT Corporation is in Pharmaceuticals
Answer: DURECT Corporation contact info: Phone number: 40******** Website: https://durect.com
Answer: DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol, DURECTs lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes that are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER platform technology, is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution in the United States.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month